Purple Biotech will present in an Oral Presentation session: ‘Interim results of a Phase 1/2 trial of NT219 in combination with cetuximab in patients with advanced/metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)’ at the ESMO Targeted Anticancer Therapies Congress 2024 (ESMO TAT) February 26-28, Paris, France. Presentation date and time: February 26 at 3:45 pm, 2024

Purple Biotech will present in an Oral Presentation session: ‘Interim results of a Phase 1/2 trial of NT219 in combination with cetuximab in patients with advanced/metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)’ at the ESMO Targeted Anticancer Therapies Congress 2024 (ESMO TAT) February 26-28, Paris, France. Presentation date and time: February 26 at 3:45 pm, 2024

in Feb 01, 2024